Association between the HMGB1/TLR4 signaling pathway and the clinicopathological features of ovarian cancer

Jiang,Caixia; Qu,Xiaoyan; Ke,Huihui; Gong,Wei; Chen,Rong; Yang,Weihong; Cheng,Zhongping

doi:10.3892/mmr.2018.9271

Association between the HMGB1/TLR4 signaling pathway and the clinicopathological features of ovarian cancer

Authors:
- Caixia Jiang
- Xiaoyan Qu
- Huihui Ke
- Wei Gong
- Rong Chen
- Weihong Yang
- Zhongping Cheng
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, P.R. China, Department of Gynecology and Obstetrics, Shanghai Pudong Hospital, Fudan University School of Medicine, Shanghai 510070, P.R. China, Department of Gynecology and Obstetrics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China
Published online on: July 10, 2018 https://doi.org/10.3892/mmr.2018.9271
Pages: 3093-3098

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, the expression levels of high‑mobility group protein B1 (HMGB1), Toll‑like receptor 4 (TLR4), nuclear factor (NF)‑κB and tumor necrosis factor (TNF)‑α in malignant epithelial ovarian cancer (MEOC) were investigated in regards to several clinicopathological characteristics. A total of 20 patients with MEOC who underwent surgery were recruited in the present study. The mRNA and protein expression of HMGB1, TLR4, NF‑κB and TNF‑α was determined in patients with MEOC and compared with expression levels in 20 patients diagnosed with benign ovarian cysts (BOC). It was demonstrated that the mRNA and protein expression of HMGB1, TLR4, NF‑κB and TNF‑α in MEOC was significantly increased, compared with the BOC group (P<0.01). The gene and protein expression of HMGB1, TLR4, NF‑κB and TNF‑α was significantly increased in the advanced tumor stage and poorly differentiated group (P<0.01). The present study suggested that the HMGB1/TLR4 signaling pathway was overactive in MEOC, and was associated with MEOC tumor cell proliferation, invasion and metastasis. Furthermore, this may have been mediated via NF‑κB signaling.

View Figures

View References

1	Jayson GC, Kohn EC, Kitchener HC and Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014. View Article : Google Scholar : PubMed/NCBI
2	Luo N, Guo J, Chen L, Yang W, Qu X and Cheng Z: ARHGAP10, downregulated in ovarian cancer, suppresses tumorigenicity of ovarian cancer cells. Cell Death Dis. 7:e21572016. View Article : Google Scholar : PubMed/NCBI
3	Wang H, Li Z, Sun Y, Xu Z, Han J, Song B, Song W, Qin C and Yin L: Relationship between high-mobility group box 1 overexpression in ovarian cancer tissue and serum: A meta-analysis. Onco Targets Ther. 8:3523–3531. 2015.PubMed/NCBI
4	Li Y, Tian J, Fu X, Chen Y, Zhang W, Yao H and Hao Q: Serum high mobility group box protein 1 as a clinical marker for ovarian cancer. Neoplasma. 61:579–584. 2014. View Article : Google Scholar : PubMed/NCBI
5	Zhou LY, Shi LY and Xiao Y: Changes of HMGB1 expression on angiogenesis of ovarian cancer and its mechanism. J Biol Regul Homeost Agents. 30:233–238. 2016.PubMed/NCBI
6	Zhang W, Tian J and Hao Q: HMGB1 combining with tumor-associated macrophages enhanced lymphangiogenesis in human epithelial ovarian cancer. Tumour Biol. 35:2175–2186. 2014. View Article : Google Scholar : PubMed/NCBI
7	Paek J, Lee M, Nam EJ, Kim SW and Kim YT: Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer. Arch Gynecol Obstet. 293:645–650. 2016. View Article : Google Scholar : PubMed/NCBI
8	Li S and Wei Y: Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity. Oncol Lett. 15:9572–9576. 2018.PubMed/NCBI
9	Ju LL, Zhao CY, Ye KF, Yang H and Zhang J: Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues. Eur Rev Med Pharmacol Sci. 20:1993–2003. 2016.PubMed/NCBI
10	Chen J, Liu X, Zhang J and Zhao Y: Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference. J Cell Physiol. 230:25792015. View Article : Google Scholar : PubMed/NCBI
11	Li Z, Block MS, Vierkant RA, Fogarty ZC, Winham SJ, Visscher DW, Kalli KR, Wang C and Goode EL: The inflammatory microenvironment in epithelial ovarian cancer: A role for TLR4 and MyD88 and related proteins. Tumor Biol. 37:13279–13286. 2016. View Article : Google Scholar
12	Husseinzadeh N and Davenport SM: Role of toll-like receptors in cervical, endometrial and ovarian cancers: A review. Gynecol Oncol. 135:359–363. 2014. View Article : Google Scholar : PubMed/NCBI
13	Prat J: FIGO Committee on Gynecologic Oncology: Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 124:1–5. 2014. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Cheng Z, Guo J, Chen L, Luo N, Yang W and Qu X: Overexpression of TMEM158 contributes to ovarian carcinogenesis. J Exp Clin Cancer Res. 34:752015. View Article : Google Scholar : PubMed/NCBI
16	Kobayashi M, Sawada K and Kimura T: Potential of integrin inhibitors for treating ovarian cancer: A literature review. Cancers (Basel). 9:pii: E83. 2017.
17	Waki K, Kawano K, Tsuda N, Ushijima K, Itoh K and Yamada A: Plasma levels of high-mobility group box 1 during peptide vaccination in patients with recurrent ovarian cancer. J Immunol Res. 2017:14236832017. View Article : Google Scholar : PubMed/NCBI
18	Sun NK, Huang SL, Chang TC and Chao CC: TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells. J Cell Physiol. 233:2489–2501. 2018. View Article : Google Scholar : PubMed/NCBI
19	Jiang C, Liu C, Guo J, Chen L, Luo N, Qu X, Yang W, Ren Q and Cheng Z: The expression of Toll-like receptors in eutopic and ectopic endometrium and its implication in the inflammatory pathogenesis of adenomyosis. Sci Rep. 7:73652017. View Article : Google Scholar : PubMed/NCBI